Trial Profile
A Phase I/IIa, Open-label, Dose-Escalation and Dose Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Efineptakin alfa (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors I-MAB Biopharma
- 14 Feb 2022 Status changed from active, no longer recruiting to completed.
- 17 Oct 2021 Planned End Date changed from 28 Oct 2021 to 31 Dec 2021.
- 17 Oct 2021 Status changed from recruiting to active, no longer recruiting.